ANI Pharmaceuticals reported a significant improvement in financial position for the period ended September 30, 2026, shifting from an accumulated deficit of $23.1 million to retained earnings of $66.3 million. Total assets increased to $1.57 billion, driven by a substantial rise in cash and cash equivalents to $420.8 million, while the company continues to focus on strategic growth through the proposed acquisition of Egetis Therapeutics AB.
ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, a 27.6% year-over-year increase driven by strong performance in its Rare Disease and Generics segments. The company narrowed its full-year revenue guidance and raised its adjusted EBITDA and EPS outlook while highlighting its pending acquisition of Egetis Therapeutics.
Term
Q3 2026
“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company. Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform.”
Nikhil Lalwani, President and CEO of ANI
“As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing. We are also executing multiple operational and strategic initiatives to achieve approximately 40% year-over-year growth in 2026 for Cortrophin and capture the significant multi-year growth opportunity ahead.”